Table 2 Clinical characteristics of respondents with PsA, stratified by time between seeking medical attention and receiving formal diagnosis
Characteristics | Total Respondents (N = 203) | <  6 Months (n = 69) | 6 Months to 4 Years (n = 68) | ≥ 5 Years (n = 66) | P Value |
|---|---|---|---|---|---|
RAPID3 cumulative score (0–30) | |||||
 Mean (SD) | 14.7 (5.8) | 14.3 (6.5) | 14.5 (5.8) | 15.4 (5.0) | 0.559 |
 Median (IQR) | 15.5 (8.5) | 14.5 (10.2) | 15.5 (8.9) | 16.3 (6.0) |  |
 Range | 1.3–29.0 | 1.3–29.0 | 2.0–24.3 | 2.0–25.2 |  |
RAPID3 disease severity category, n (%) | Â | Â | Â | Â | 0.688 |
 Near remission (1–3) | 5 (2.5) | 2 (2.9) | 2 (2.9) | 1 (1.5) |  |
 Low (4–6) | 14 (6.9) | 6 (8.7) | 5 (7.4) | 3 (4.5) |  |
 Medium (7–12) | 45 (22.2) | 18 (26.1) | 16 (23.5) | 11 (16.7) |  |
 High (13–30) | 139 (68.5) | 43 (62.3) | 45 (66.2) | 51 (77.3) |  |
Years since first symptom experienced | |||||
 Mean (SD)a | 15.1 (11.8) | 13.4 (13.2) | 10.7 (7.6) | 21.3 (11.5) | < 0.001 |
 Median (IQR) | 12.0 (13.0) | 8.0 (13.0) | 9.0 (10.0) | 18.0 (18.0) |  |
 Range | 0–60.0 | 0–60.0 | 1.0–39.0 | 3.0–52.0 |  |
Years since official diagnosis | |||||
 Mean (SD) | 8.7 (9.6) | 10.8 (12.4) | 8.1 (7.3) | 7.3 (7.9) | 0.073 |
 Median (IQR) | 6.0 (10.0) | 7.0 (11.0) | 6.5 (9.0) | 5.0 (8.0) |  |
 Range | 0–60.0 | 0–60.0 | 0–39.0 | 0–42.0 |  |
Extent of psoriasis (assessed by area covered in number of palms), n (%)b | Â | Â | Â | Â | 0.259 |
 Little to no psoriasis (< 1 palm) | 105 (51.7) | 33 (47.8) | 43 (63.2) | 29 (43.9) |  |
 Only a few patches (1–2 palms) | 45 (22.2) | 14 (20.3) | 12 (17.6) | 19 (28.8) |  |
 Scattered patches (3–10 palms) | 41 (20.2) | 17 (24.6) | 9 (13.2) | 15 (22.7) |  |
 Extensive psoriasis (> 10 palms) | 12 (5.9) | 5 (7.2) | 4 (5.9) | 3 (4.5) |  |
Current symptoms (in ≥ 50% of respondents), n (%)c | |||||
 Joint pain | 176 (86.7) | 57 (82.6) | 61 (89.7) | 58 (87.9) | 0.498 |
 Fatigue | 169 (83.3) | 56 (81.2) | 57 (83.8) | 56 (84.8) | 0.867 |
 Stiffness | 159 (78.3) | 53 (76.8) | 51 (75.0) | 55 (83.3) | 0.456 |
 Swollen joints | 127 (62.6) | 42 (60.9) | 45 (66.2) | 40 (60.6) | 0.759 |
 Reduced range of motion in the joints of the arms and legs | 122 (60.1) | 43 (62.3) | 38 (55.9) | 41 (62.1) | 0.679 |
 Back pain | 119 (58.6) | 39 (56.5) | 37 (54.4) | 43 (65.2) | 0.414 |
 Foot problems | 115 (56.7) | 34 (49.3) | 37 (54.4) | 44 (66.7) | 0.115 |
 Tendon or ligament paina | 109 (53.7) | 27 (39.1) | 37 (54.4) | 45 (68.2) | 0.003 |
 Difficulty walking | 108 (53.2) | 39 (56.5) | 33 (48.5) | 36 (54.5) | 0.615 |
 Reduced range of motion in spine and/or hips | 107 (52.7) | 34 (49.3) | 34 (50.0) | 39 (59.1) | 0.459 |
Other health conditions (in ≥ 25% of respondents), n (%)c | |||||
 Depression | 126 (62.1) | 35 (55.1) | 49 (72.1) | 39 (59.1) | 0.105 |
 Anxiety | 118 (58.1) | 38 (55.1) | 40 (58.8) | 40 (60.6) | 0.806 |
 Hypertension | 97 (47.8) | 39 (56.5) | 28 (41.2) | 30 (45.5) | 0.178 |
 Migraines | 90 (44.3) | 24 (34.8) | 34 (50.0) | 32 (48.5) | 0.142 |
 Fibromyalgiaa | 77 (37.9) | 18 (26.1) | 30 (44.1) | 29 (43.9) | 0.043 |
 Irritable bowel syndromea | 76 (37.4) | 16 (23.2) | 26 (38.2) | 34 (51.5) | 0.003 |
 Seasonal allergies | 70 (34.5) | 24 (34.8) | 20 (29.4) | 26 (39.4) | 0.464 |
 Dyslipidemia | 64 (31.5) | 22 (31.9) | 19 (27.9) | 23 (34.8) | 0.689 |
 Gastroesophageal reflux disease | 60 (29.6) | 22 (31.9) | 17 (25.0) | 21 (31.8) | 0.604 |
 Sleep apnea | 53 (26.1) | 15 (21.7) | 18 (26.5) | 20 (30.3) | 0.501 |
Prescription medication ever taken, n (%)c | |||||
 Biologic | 176 (86.7) | – | – | – | – |
 Nonbiologic DMARD | 174 (85.7) | – | – | – | – |
 Antidepressant | 109 (53.7) | – | – | – | – |
 Steroid medication | 162 (79.8) | – | – | – | – |
 NSAID | 167 (82.3) | – | – | – | – |
 Opioid pain medication | 96 (47.3) | – | – | – | – |
 Other pain medication | 132 (65.0) | – | – | – | – |
 Sleep medication | 67 (33.0) | – | – | – | – |
 Other | 58 (28.6) | – | – | – | – |
 None | 3 (1.5) | – | – | – | – |